Keytruda biosimilars near, but face steep commercial hurdles

· Health · United States

BioPharma Dive reports that biosimilars to Keytruda, Merck's flagship cancer immunotherapy, are approaching as a patent cliff looms for the blockbuster. Even so, the deck may be stacked against them gaining widespread traction. Keytruda is one of the world's largest-selling medicines, so its loss of exclusivity is among the most consequential patent events in the industry. Biosimilar makers typically win share by competing on price once patents lapse, but the article signals structural obstacles could limit uptake for this particular product. The report does not detail which barriers are decisive. The outcome will shape how quickly lower-cost versions reach patients and how much revenue Merck cedes as the cliff arrives.

Why it matters：Keytruda is among the industry's biggest revenue generators, so how its biosimilar market develops will set expectations for pricing, payer behavior and the returns of the next wave of off-patent cancer biologics.

Key points

  • Keytruda is Merck's flagship blockbuster facing an approaching patent cliff.
  • Biosimilar competition typically hinges on price, but the report suggests uptake may be limited.

Sources (original reporting)

More stories from this day